A PHASE Ib MULTICENTER OPEN-LABEL STUDY TO EVALUATE THE SAFETY EFFICACY AND PHARMAKOKINETICS OF RO6958688 IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION
Brief description of study
The purpose of this study is to explore the effects, good or bad, of cibisatamab, atezolizumab, obinutuzumab, and tocilizumab on patients with CRC. In this study, you will first get treated with obinutuzumab (hereafter referred to as pretreatment with obinutuzumab). About 2 weeks later, you will then get treated with cibisatamab and atezolizumab. If you have a bad reaction to cibisatamab and atezolizumab, you may also get treated with tocilizumab.
Clinical Study Identifier: s18-01932
ClinicalTrials.gov Identifier: NCT03866239
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
